Faculty Collaboration Database

Brachytherapy and continuous infusion 5-fluorouracil for treatment of locally advanced, lymph node negative, prostate cancer: a phase I trial. Cancer 1996 Mar 01;77(5):924-7

Date

03/01/1996

Pubmed ID

8608485

Scopus ID

2-s2.0-0030047318 (requires institutional sign-in at Scopus site)   5 Citations

Abstract

BACKGROUND: 5-fluorouracil (5-FU) is a known radiosensitizer that enhances efficacy, in vivo and in vitro, when administered during radiotherapy. The following study was performed to evaluate the toxicity of continuous infusion 5-FU administered concomitant with brachytherapy in patients with locally advanced prostate cancer.

METHODS: Over a 26-month period, a total of 25 patients with newly diagnosed, locally advanced prostate cancer underwent radioactive gold (Au198) brachytherapy. Twenty-four of 25 patients were surgically staged and confirmed node negative. Au198 seed placement was performed transperineally under fluoroscopic and ultrasonographic guidance using an average of 195 mCi of Au198. Within 4 hours after seed placement, 25 patients received 5-FU administered as a continuous infusion over 4 days, at 1 of 8 dose levels ranging from 200-1100 mg/m2/day. Patients had clinical follow-up for a minimum of 1 year. Decreases in serum prostate specific antigen (PSA) and prostate volume (normalized to pretreatment values) were determined at 12 months.

RESULTS: 5-FU associated toxicity was negligible, with Grade 1 nausea in four patients and no Grade 2 or higher toxicity. No unique locoregional toxicity was noted. At 12 months after treatment, PSA values decreased on average to 16.4% of pretreatment values. Twelve-month prostate volumes decreased to 55% of the pretreatment values.

CONCLUSIONS: These findings suggest that continuous infusion 5-FU can be administered safely concomitant with brachytherapy at doses up to 1100 mg/m2 per day for 4 days.

Author List

See WA, Dreicer R, Wheeler JA, Forest PK, Loening S

MESH terms used to index this publication - Major topics in bold

Aged
Antineoplastic Agents
Brachytherapy
Combined Modality Therapy
Fluorouracil
Gold Radioisotopes
Humans
Infusions, Intravenous
Lymphatic Metastasis
Male
Middle Aged
Prostatic Neoplasms
Radiation-Sensitizing Agents
Radiotherapy Dosage